13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001826434
Total reported value
$813.2M
$813.2M
25 檔
19.1%
During the Q2 2024 filing period, Tri Locum Partners LP (CIK: 0001826434) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $813.2M across 25 reported positions.
During Q2 2024, Tri Locum Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 10.48% | -1.21% | +15.08% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 8.11% | +1.51% | +166.46% | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 7.85% | -8.20% | EXIT | |
| 4 | AMGN | Amgen Inc | Stock-Healthcare | 6.50% | — | — | |
| 5 | NTRA | Natera Inc | Stock-Healthcare | 6.31% | — | +21.29% | |
| 6 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 6.24% | +5.13% | +198.42% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 5.36% | — | — | |
| 8 | ✓ | Merus N V | Stock-Other | 5.02% | — | +17.18% | |
| 9 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 4.65% | — | +104.46% | |
| 10 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 4.63% | -3.08% | +22.49% | |
| 11 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 4.51% | — | +465.54% | |
| 12 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 4.23% | — | +0.00% | |
| 13 | PFE | Pfizer Inc | Stock-Healthcare | 4.22% | — | — | |
| 14 | UTHR | United Therapeutics CORP | Stock-Healthcare | 4.04% | -2.73% | — | |
| 15 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.99% | — | +25.64% | |
| 16 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.76% | — | — | |
| 17 | STVN | Stevanato Group S.p.A. | Stock-Other | 2.62% | — | — | |
| 18 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 2.30% | — | — | |
| 19 | PCVX | Vaxcyte Inc | Stock-Other | 2.16% | — | — | |
| 20 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.01% | — | -50.85% | |
| 21 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.89% | — | — | |
| 22 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.79% | — | -29.27% | |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.70% | — | +0.65% | |
| 24 | KRRO | Korro Bio Inc | Stock-Other | 0.61% | — | — | |
| 25 | ✓ | Femasys Inc | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Tri Locum Partners LP reported a total U.S. public equity portfolio value of $813.2M across 25 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, ARGX, ASND) accounted for 19.1% of total reported equity market value during Q2 2024.
During Q2 2024, Tri Locum Partners LP's top holdings by market value included TEVA (10.5%)、ARGX (8.1%)、ASND (7.8%). The largest single position, TEVA, represented 10.5% of total portfolio value.
In Q2 2024, Tri Locum Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.